arrow
K

Kavita Raj

university college london hospitals nhs foundation trust
H指数:31
被引数:3,731

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome in young adults: A retrospective study on behalf of the EBMT Chronic Malignancies Working Party

异基因造血细胞移植治疗年轻成人骨髓增生异常综合征:代表EBMT慢性恶性疾病工作组进行的回顾性研究

2026-09-300
OA
The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

2016年至2022年间EBMT中心中,17p缺失的骨髓瘤患者在接受AHSCT时,细胞遗传学异常的累积效应对其预后的影响

2026-09-050
OAAI
Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience

三联疗法(gilteritinib、azacitidine和venetoclax)在FMS样酪氨酸激酶3(FLT3)突变复发/难治性急性髓系白血病中的真实世界疗效:一项英国单中心经验

2026-08-210
OAAI
Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone—a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT

异基因造血细胞移植治疗伴有阵发性睡眠性血红蛋白尿克隆异常的骨髓增生异常综合征——欧洲血液和骨髓移植学会慢性恶性病和重症再生障碍性贫血工作组代为研究

2026-08-130
PRE
Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation

定义具有极高风险细胞遗传学特征的骨髓增生异常综合征患者的一个亚组,其在异基因造血细胞移植后表现出相对更良好的预后

2026-06-280
OAAI
Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT

近年来骨髓增生异常综合征患者移植趋势:EBMT慢性恶性疾病工作组登记研究

2026-05-280
OAAI
Fludarabine–Treosulfan (FT10) Conditioning in Older AML Patients Undergoing Haploidentical Transplantation: A Prospective Italian Study with External Comparison to the Haplo-UK Reduced-Intensity Conditioning Cohort
2026-05-110
PRE
Fludarabine-treosulfan compared with fludarabine-melphalan conditioning for adult acute lymphoblastic leukemia.

氟达拉滨-曲奥硫嘌呤与氟达拉滨-美法仑预处理方案在成人急性淋巴细胞白血病中的比较。

2026-01-010
OAAI
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm

一项由EBMT慢性恶性疾病工作组代表进行的关于异基因造血细胞移植治疗骨髓纤维化的欧洲调查:聚焦于JAK抑制剂的“真实世界”经验、脾肿大管理以及移植算法中的新型药物

2025-12-240
OAAI
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

移植预处理强度(TCI)评分可预测骨髓纤维化患者的allo-HCT结局:EBMT慢性恶性疾病工作组的研究

2025-10-150
OA
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT

供者类型对骨髓纤维化患者异基因造血细胞移植后结局的影响:欧洲血液和骨髓移植学会慢性恶性疾病工作组的研究

2025-08-290
OAAI
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT

Conditioning强度在年龄≥50岁接受异基因造血细胞移植(allo-HCT)的骨髓增生异常综合征患者中的研究:代表EBMT慢性恶性疾病工作组的研究

2025-08-290
OAAI
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

不同初始干细胞移植策略治疗多发性骨髓瘤的结局:EBMT慢性恶性疾病工作组从统计学角度进行的分析

2025-07-300
OAAI
A comparison of Cryopreserved and non-Cryopreserved Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A study from the Chronic Malignancies Working Party of the EBMT

比较冷冻保存与非冷冻保存的外周血造血干细胞在多发性骨髓瘤自体移植中的应用:EBMT慢性恶性疾病工作组的研究

2025-03-070
PRE
Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT
2025-01-011
OAAI
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT
2024-11-280
PRE
Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms
2024-09-111
OAAI
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
2024-03-280
OAAI
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT

VEXAS综合征的异基因造血细胞移植: EBMT的多中心研究结果

2024-03-1516
OAAI